AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take ...

One of the sources cited by Reuters said that international reference pricing presents an "existential threat to the industry ...

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales ...

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

All U.S. service members aboard the USS Harry S. Truman have been accounted for and are safe after a fighter jet, an F/A-18E ...

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

AbbVie Inc.'s strong fundamentals, healthy dividends, and acceptable forward P/Es for the medium term make a case. Read more ...

The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target. Not surprisingly, according to ...